Tag Archives: biotechnology

Skinmedica, Inc. and, i.e., Disclaimer

Posted on October 2, 2013 by Warren Woessner

The Fed. Cir. has been pretty hard on defendants alleging disclaimer of claim scope in recent decisions but that was not the case here. But what caught my attention is that Judge Prost spent four pages of his opinion on … Continue reading →

Posted in Claim Interpretation | Tagged biotechnology, biotechnology law, Federal Circuit, intellectual property, ip, Judge Prost, Patent Law, patents, Skinmedica v Histogen, Warren Woessner | 3 Comments

Dr. Watson, Genomics and the Law

Posted on September 3, 2013 by Warren Woessner

Since the legal tsunami of court decisions affecting many aspects of life sciences – from patents on Round-UpTM Ready soybeans to “companion diagnostics” – has rolled back out to the sea of summer break, I have found time to reflect … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged biotechnology, BRCA DNA, Dr. James Watson, Federal Circuit, monsanto, Myriad, Patent Law, Round-Up, Supreme Court, Warren Woessner | 1 Comment

Review of Indian Working Requirements

Posted on August 21, 2013 by Warren Woessner

This newsletter (attached below) from a leading Indian firm, contains a good review of the perils of the working requirement in India. It also provides a good summary of three recent decisions holding pharma patents invalid for obviousness. What is striking is … Continue reading →

Posted in Int'l Practice and Policy | Tagged biotechnology, biotechnology law, india patent law, intellectual property, ip, Lakshmikumaran & Sridharan, Patent Law, patents, Warren Woessner | Leave a comment

Evidentiary, My Dear Watson; Biosig, Instruments v. Nautilus, Inc.

Posted on August 1, 2013 by Warren Woessner

This is a guest post from Ronald Schutz of Robins, Kaplan, Miller & Ciresi. In Biosig, Instruments v. Nautilus, Inc., a unanimous panel of the Federal Circuit had little trouble deducing the definiteness of the patent at issue despite a … Continue reading →